Markets
Pfizer Building Facade
(Getty Images)

Pfizer reports earnings beat and boosts guidance as Metsera bid-off heats up

Pfizer reported earnings on Tuesday.

J. Edward Moreno

Pfizer rose in early trading after it reported earnings results on Tuesday that beat Wall Street estimates as the company is embroiled in the middle of a bid-off for obesity biotech Metsera.

The pharmaceutical giant reported adjusted earnings per share of $0.87, compared to the $0.63 analysts polled by FactSet were expecting. The company also narrowed its full-year adjusted profit per share guidance to between $3.00 and $3.15, from between $2.90 and $3.10, which equates to a mild boost to the expected midpoint.

It also reported $16.6 billion in revenue for the quarter, just above the $16.5 billion the Street was penciling in.

The company is down about 7% since the start of the year amid industry-wide headwinds like tariffs as well as its own struggle to secure its next source of revenue growth.

Meanwhile, Pfizer launched a legal battle this week against Novo Nordisk — its Danish competitor and maker of Ozempic — for seeking to intercept its acquisition bid for Metsera, an obesity biotech working on a next-generation GLP-1 drug.

Metsera said on Monday that both Novo and Pfizer upped their bids for the company, but Novo's was still superior to Pfizer’s.

The spat underscores just how much the weight-loss medication race is heating up. Earlier this year, Pfizer scrapped a GLP-1 pill it was developing after data from clinical trails fell short. Novo, while first to the GLP-1 market, is watching Eli Lilly’s drugs eat its lunch.

More Markets

See all Markets
Netflix's Upfront 2025

Netflix sinks on lower-than-expected earnings forecast

Netflix’s report dropped on the same day it officially went all-cash in its bid for Warner Bros. Discovery.

markets

United Airlines rallies after Q4 earnings and Q1 profit guidance top estimates

Shares of United Airlines are rising after the bell on Tuesday, following the release of the carrier’s fourth-quarter and full-year earnings report.

United posted adjusted earnings per share of $3.10 in Q4, above the $2.92 per share expected by Wall Street analysts polled by Bloomberg. Sales of $15.4 billion were roughly in line with the consensus estimate.

The airline also:

  • Forecast full-year earnings per share between $12 and $14, bracketing Wall Street’s call for $13.04. For Q1, management sees EPS between $1.00 and $1.50, the midpoint of which is above the $1.16 expected by Wall Street.

  • Booked $13.93 billion in passenger revenue on the quarter, up nearly 5% year over year.

“Strong revenue momentum has continued into 2026,” according the company’s press release. “The week ending January 4th was the highest flown revenue week in United history, and the week ending January 11th was the highest ticketing week and the highest week for business sales in United history.”

UAL’s premium ticket revenue climbed 9% compared to a 7% increase in basic economy revenue. The “K-shaped economy” has become increasingly visible in travel trends at major US airlines. Last week, Delta’s revenue from first-class and business passengers eclipsed its main cabin revenue for the first time.

President Trump Delivers An Announcement From The Oval Office

Pharma largely unfazed as Greenland tariffs roil markets

Drugmakers, which have spent the past six months reaching tariff deals with Trump, seem to expect some immunity from a new batch of tariffs on European countries.

markets

POET Technologies nears multiyear high on strong call demand after flagship product wins award

POET Technologies is surging on heavy volumes and high call demand after announcing that it won a Product Innovation Award at China’s Infostone awards.

The honor went to the optical communications company’s flagship product, the Teralight, which uses light to move data between chips.

“Unveiled less than a year ago at the 2025 OFC Conference, POET Teralight has driven commercial interest in the Company because of its highly integrated design and complete optical system-on-chip architecture that simplifies module development,” per the press release.

This award may be the latest excuse to buy the stock, which is up over 40% year to date.

Call activity is elevated, with nearly 37,000 having changed hands as of 10:55 a.m. ET, well above the 20-day average of 28,030 for a full session. Shares are approaching their multi-year high of $9.41.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.